# Premerger Notification; Reporting and Waiting Period Requirements
> **US Federal Trade Commission** · Final rule. · Published 2013-11-15 · Effective 2013-12-16 · 78 FR 68705
## Document
- **Document number:** 2013-27027
- **Category:** final-rule
- **Agency:** US Federal Trade Commission
- **Federal Register citation:** 78 FR 68705
- **CFR reference:** 16 CFR 801
- **Publication date:** 2013-11-15
- **Effective date:** 2013-12-16
## Abstract

The Federal Trade Commission ("Commission" or "FTC"), with the concurrence of the Assistant Attorney General, Antitrust Division, Department of Justice (the "Assistant Attorney General" or the "Antitrust Division") (together the "Agencies"), is amending the Hart-Scott-Rodino Premerger Notification Rules (the "Rules") in order to provide a framework for determining when a transaction involving the transfer of rights to a patent or part of a patent in the pharmaceutical, including biologics, and medicine manufacturing industry (North American Industry Classification System Industry Group 3254) ("pharmaceutical industry") is reportable under the Hart Scott Rodino Act ("the Act," "HSR Act" or "HSR"). This final rule defines and applies the concepts of "all commercially significant rights," "limited manufacturing rights," and "co-rights" in determining whether the rights transferred with regard to a patent or a part of a patent in the pharmaceutical industry constitute a potentially reportable asset acquisition under the Act.

## Source
- [Federal Register document](https://www.federalregister.gov/documents/2013/11/15/2013-27027/premerger-notification-reporting-and-waiting-period-requirements)
---
*AI Analytics · CC0 1.0*